730 related articles for article (PubMed ID: 9219512)
1. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
2. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Wedge SR; Newlands ES
Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262
[TBL] [Abstract][Full Text] [Related]
3. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
4. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
6. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
[TBL] [Abstract][Full Text] [Related]
7. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
9. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
[TBL] [Abstract][Full Text] [Related]
10. O6-benzylguanine-mediated enhancement of chemotherapy.
Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
[TBL] [Abstract][Full Text] [Related]
11. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
12. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of temozolomide combined with X-irradiation.
Wedge SR; Porteous JK; Glaser MG; Marcus K; Newlands ES
Anticancer Drugs; 1997 Jan; 8(1):92-7. PubMed ID: 9147618
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
16. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C
Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196
[TBL] [Abstract][Full Text] [Related]
17. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
18. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Reese JS; Davis BM; Liu L; Gerson SL
Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
